FDA places SB-generated CAR T-cell therapy on clinical holdJune 19, 2018Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersAggressive Lymphomas
Peripheral blood MRD correlates with treatment benefit in CLLJune 18, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
‘Excellent’ survival with HCT despite early treatment failure in FLJune 16, 2018Lymphoma & Plasma Cell DisordersTransplantationAggressive Lymphomas
Interim PET scans identify HL patients with better outcomesJune 16, 2018Lymphoma & Plasma Cell DisordersHodgkin LymphomaAggressive Lymphomas
FDA grants pembrolizumab accelerated approval for PMBCLJune 14, 2018Lymphoma & Plasma Cell DisordersPharmacyAggressive Lymphomas
Ibrutinib and venetoclax combo promising in frontline CLLJune 13, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Chemo-free combo provides potential first-line option for FLJune 12, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
FDA approves venetoclax for CLL/SLL with or without del 17pJune 10, 2018Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaAggressive Lymphomas
Polatuzumab plus BR improves efficacy in DLBCLJune 8, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Single-agent acalabrutinib ‘impressive’ in patients with WMJune 6, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Older, cheaper drug formulation to remain availableMay 21, 2018Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersTransplantationNon-Hodgkin LymphomaAggressive Lymphomas
Umbralisib has ‘distinct’ safety profileMay 16, 2018Lymphoma & Plasma Cell DisordersHodgkin LymphomaNon-Hodgkin LymphomaAggressive Lymphomas
‘Long-term benefits’ with nivolumab in cHLMay 9, 2018Lymphoma & Plasma Cell DisordersHodgkin LymphomaAggressive Lymphomas
Drug granted fast track designations for FL, DLBCLMay 5, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
FDA issues CRL for proposed biosimilar rituximabMay 3, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
